Experienced in Legius Syndrome

Dr. Joel R. Hecht

Hematology Oncology | Gastroenterology
The Regents Of The University Of California
2020 Santa Monica Blvd, Suite 210, 
Santa Monica, CA 
Offers Telehealth
Experienced in Legius Syndrome
The Regents Of The University Of California
2020 Santa Monica Blvd, Suite 210, 
Santa Monica, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Hecht is a Hematologist Oncology specialist and a Gastroenterologist in Santa Monica, California. Dr. Hecht is rated as an Experienced provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Neuroendocrine Tumor, Familial Pancreatic Cancer, and Liver Embolization.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Gastroenterology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
Enrollment Status: Completed
Publish Date: March 01, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy
An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First-Line Therapy
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)
An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)
Enrollment Status: Withdrawn
Publish Date: February 01, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

11 Total Publications

Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.
Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma.
Journal: The oncologist
Published: June 03, 2024
Similar Doctors
Experienced in Legius Syndrome
Dr. Hung N. Tran
Hematology | Oncology | Hematology Oncology
Experienced in Legius Syndrome
Dr. Hung N. Tran
Hematology | Oncology | Hematology Oncology

Los Angeles Medical Center

4950 W Sunset Blvd, 
Los Angeles, CA 
 (11.4 miles away)
833-574-2273
Languages Spoken:
English

Hung Tran is a Hematologist Oncology specialist and an Oncologist in Los Angeles, California. Dr. Tran is rated as an Advanced provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Acute Lymphoblastic Leukemia (ALL), and Langerhans Cell Histiocytosis.

Experienced in Legius Syndrome
Dr. Jayaram S. Bharadwaj
Hematology Oncology | Oncology
Experienced in Legius Syndrome
Dr. Jayaram S. Bharadwaj
Hematology Oncology | Oncology

Los Angeles Hematology-Oncology Medical Group

1801 W Romneya Dr, Suite 203, 
Anaheim, CA 
 (32.9 miles away)
714-999-1465
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jayaram Bharadwaj is a Hematologist Oncology specialist and an Oncologist in Anaheim, California. Dr. Bharadwaj is rated as a Distinguished provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Drug-Induced Thrombocytopenia, Thrombocytopenia, Agranulocytosis, and Anemia.

Experienced in Legius Syndrome
Dr. George Ferenczi
Gastroenterology
Experienced in Legius Syndrome
Dr. George Ferenczi
Gastroenterology

Citrus Valley Gastroenterology A Medical Corporation

500 W San Bernardino Rd, Suite B, 
Covina, CA 
 (33.5 miles away)
626-960-2326
Languages Spoken:
English
See accepted insurances

George Ferenczi is a Gastroenterologist in Covina, California. Dr. Ferenczi is rated as an Advanced provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Hemorrhoids, Diverticular Disease, Colonoscopy, and Gastrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hecht's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile